CD15 Expression Does Not Identify a Phenotypically or Genetically Distinct Glioblastoma Population.

Area of Science:

• Oncology
• Cancer Stem Cell Biology
• Neuro-oncology

Background:

• Glioblastoma (GB) growth and regeneration are hypothesized to be driven by cancer stem cells.
• Identifying reliable cancer stem cell markers is crucial for developing targeted GB therapies.
• CD15 has been proposed as a potential marker for glioblastoma stem cells.

Purpose of the Study:

• To investigate the utility of CD15 as a cancer stem cell marker in glioblastoma.
• To determine if CD15 can isolate a distinct subpopulation of glioblastoma stem cells.
• To assess the functional and molecular characteristics of CD15-positive and CD15-negative glioblastoma cells.

Main Methods:

• Comparative analysis of CD15-positive (CD15+) and CD15-negative (CD15-) cells from patient-derived glioblastoma tumors and cell lines.
• Assessment of cell proliferation, cytogenetics, and gene expression profiles.
• In vitro and in vivo tumor reconstitution assays using sorted CD15+ and CD15- cells.

Main Results:

• CD15+ cells showed reduced proliferation in patient tumors but not in vitro.
• No significant differences in proliferation, cytogenetics, or gene expression were observed between CD15+ and CD15- cells in vitro.
• Both CD15+ and CD15- cells could reconstitute heterogeneous glioblastoma populations and form tumors in vivo.
• CD15+ and CD15- cells demonstrated interconversion between states in vitro.

Conclusions:

• CD15 does not appear to be a reliable marker for isolating a distinct glioblastoma stem cell population.
• The phenotypic and genomic characteristics of CD15+ and CD15- cells are not significantly different.
• The interconvertibility of CD15 states challenges its utility as a specific therapeutic target for glioblastoma stem cells.